NRAS G12S

Clinical trials for NRAS G12S explained in plain language.

Never miss a new study

Get alerted when new NRAS G12S trials appear

Sign up with your email to follow new studies for NRAS G12S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New immunotherapy option for High-Risk pancreatic cancer patients

Disease control AVAILABLE

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

Matched conditions: NRAS G12S

Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:36 UTC

NRAS G12S

Get alerted when new NRAS G12S trials appear

New immunotherapy option for High-Risk pancreatic cancer patients